Grappling with oncology, clinical research, quality of life, prognostication, communication, education, rabbitohs, wallabies, cricket, and other enigmas
2011 PhD student → 2025 drug development oncologist.
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis
https://t.co/U8xUGsAl2e
Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial.
Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer
@NicholasZaorsky@yilun_sun@StatMatt9@DrHowardSandler@drjefstathiou@Soum_Roy_RadOnc@DrPaulNguyen@jeshoag@PBarataMD@angela_jia_@MSteinbergMD@AmarUKishan@DrSpratticus@OncoAlert 🚨
@Silke_Gillessen@AOmlin@weoncologists
Just published a paper co-authored with early-phase trial patients.
It took far longer than it should have… a sign of how undervalued patient experience still is in oncology.
Cancer drug development must be human-centred, not just molecule-centred.
🔗: https://t.co/gp94RUBGsB
The discussant @ShannonWestin intrigued by the OS curves in the ECHO trial which although not significant currently may improve with time. Also pointing out that PFS was excellent in both arms.
Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!
Rejected within 24 hours.
That’s how my academic journey really started.
My writing has never been the same since.
Here’s what I learned from 300+ submissions:
Too many papers get rejected instantly.
Honored to be named Program Director for GI Medical Oncology @MGHCancerCenter , focused on CRC, Anal & NET. Grateful to collaborate with incredible colleagues like @KlempnerSam leading UGI and Harsh Singh joining us for HBP. excited to build on innovation & equity in cancer care.
What an amazing feat the @BalcoMedical team pulled off .. meeting attended by >1000 with almost 200 from india, 12 globally from australia, NZ, UK, USA, Lebanon, Switzerland, singapore. key tracks were mini Accord research workshop, communication skills with role play to train Oncologist into communicating prognosis and having end of life conversations with the patients and caregivers, radiotherapy contouring workshop, surgery workshop for head neck cancers. choosing wisely themed GIGU and lung Cancer, cancer prevention workshop, which mainly discussed HPV vaccine implementation, district level cancer prevention programmes. This was attended by state level, health officers and on ground level. Mitanin/Asha workers from Chhattisgarh. meeting was attended by 65 oncology students all over the country. Top 10 posters will be published in @ecancer . Looking forward to September 2026, .. have an amazing line up of @oncology_bg , ian prof Tannock, @prof_gina_brown@ajumathew_@lateuwen and more ! Thank you to @TataMemorial@ACTREC_TMC@CancerGridIndia@ASCO@myESMO@csoncol@Shrikhande_SV@JavleMilind@MDAndersonNews@VanitaNoronha@nitaSnair